CTRI/2023/11/060203尚未招募3 期
A three-arm, parallel group, open label, randomized trial of three supplements for the nutritional management of moderate wasting in children 6-24m of age with acute illness. - Nutri-MAM Study
Center for Public Health Kinetics0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Age 6-24 months, and
- •2.Moderately wasted i.e. WLZ =-2 and > -3 or MUAC < 125 mm and > 115 mm, and
- •3.Presenting with any of the following acute illnesses at a facility out-patient clinic or discharged from hospital after <7d for any of the following:
- •a.diarrhea, defined as 3 or more loose or watery
- •stools (with or without blood) in the previous
- •24 hours, and no dehydration on assessment. If
- •the child has dehydration, the dehydration will
- •be treated re-assessing for recruitment, or
- •b.pneumonia, defined as presence before of fast
- •breathing or chest indrawing, or
- •c.Non-malarial fever, defined as reported or
- •measured (= 38?C) fever of >3 days but < 7 days
- •d.malaria, defined as reported or measured (=
- •38?C) fever and positive rapid diagnostic test, or
- •4. Consent for study participation from parent or legal guardian
排除标准
- •1.Severe acute malnutrition (WLZ < -3 or MUAC <115mm or oedema of both feet)
- •2.General danger sign (lethargic/unconscious, convulsions, unable to drink, vomits everything)
- •3.Severe illness (severe pneumonia or very severe disease, severe dehydration, neck stiffness)
- •4.Persistent diarrhoea (=14d)
- •5.Chronic infections/illness or disability, e.g. TB, HIV, congenital defects, cerebral palsy
- •6.Require hospital admission
- •7. Well child attended clinic only for routine growth monitoring or immunization
- •8.Child receiving food supplements for moderate wasting
- •9.Treated for moderate wasting in the previous 3 months
- •10.Previously enrolled in the study
- •11. Child lives outside the study area
研究者
相似试验
进行中(未招募)
不适用
Pharmacodynamic effects of lixisenatide compared to liraglutide in patients with type 2 diabetes not adequately controlled with insulin glargine with or without metformin.Type 2 Diabetes mellitusMedDRA version: 15.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2012-000027-40-DESanofi-Aventis Recherche & Développement
尚未招募
3 期
olanzipine antiemtic studyCTRI/2018/12/016643Tata Memorial Hospital
进行中(未招募)
1 期
A phase 3, open label, randomised, parallel group study to compare the effect on prevention and resolution of treatment related adverse events of a simplified, once daily regimen of a fixed dose combination tablet of emtricitabine and tenofovir DF versus twice daily co-formulated zidovudine and lamivudine (Combivir®) or zidovudine and lamivudine, in virologically suppressed, HIV infected patients taking efavirenz. - SWEET StudyHuman immunodeficiency virus (HIV-1) infectionMedDRA version: 7.0Level: PTClassification code 10020161EUCTR2004-002254-59-GBGilead Sciences Limited220
进行中(未招募)
1 期
A phase 3, open label, randomised, parallel group study to compare the effect on prevention and resolution of treatment related adverse events of a simplified, once daily regimen of a fixed dose combination tablet of emtricitabine and tenofovir DF versus twice daily co-formulated zidovudine and lamivudine (Combivir®) or zidovudine and lamivudine, in virologically suppressed, HIV infected patients taking efavirenz. - SWEET StudyHuman immunodeficiency virus (HIV-1) infectionMedDRA version: 7.0 Level: PT Classification code 10020161EUCTR2004-002254-59-IEGilead Sciences Limited220
进行中(未招募)
不适用
Effect of traditional ayurvedic formulation vs yoga vs conventional treatment in patients with Hypothyroidism.CTRI/2021/12/038780Patanjali Research Institute governed by Patanjali Research Foundation Trust
